{"preliminary_commentary":{"by_channel":{"x_thread":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"name":"hypo-FLAME 2.0","nct_id":"NCT04045717","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=hypo-flame-2-0-nct04045717. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"SBRT technique with 35 Gy in 5 fractions to the whole prostate gland and an additional simultaneously integrated focal boost to the tumor nodule(s) visible on MRI up to 50 Gy (overall treatment time (OTT) = 15 days).","label":"Hypo-FLAME 2.0","type":"EXPERIMENTAL"}],"collaborators":["The Netherlands Cancer Institute","Radboud University Medical Center","Kom Op Tegen Kanker"],"completion_date":{"date":"2032-02-16","type":"ESTIMATED"},"conditions":["Prostate Adenocarcinoma","Prostate Cancer","Prostate Neoplasm"],"enrollment":{"count":124,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Hypo-FLAME 2.0 study","otherNames":[],"type":"RADIATION"}],"last_update":"2023-12-01","lead_sponsor":"Universitaire Ziekenhuizen KU Leuven","official_title":"Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer 2.0","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2022-06-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Acute toxicity","timeFrame":"90 days after first radiation treatment"}],"references":[{"citation":"De Cock L, Draulans C, Pos FJ, Isebaert S, De Roover R, van der Heide UA, Smeenk RJ, Kunze-Busch M, van der Voort van Zyp J, de Boer H, Kerkmeijer LGW, Haustermans K. From once-weekly to semi-weekly whole prostate gland stereotactic radiotherapy with focal boosting: Primary endpoint analysis of the multicenter phase II hypo-FLAME 2.0 trial. Radiother Oncol. 2023 Aug;185:109713. doi: 10.1016/j.radonc.2023.109713. Epub 2023 May 11.","pmid":"37178932","type":"DERIVED"}],"start_date":{"date":"2020-04-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer 2.0","url":"https://clinicaltrials.gov/study/NCT04045717"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/hypo-flame-2-0-nct04045717"}